Mycophenolate mofetil appears to be effective second-line treatment for TED

Posted on

Mycophenolate mofetil (MMF) appears safe and effective as a second-line immunosuppressive agent in patients with thyroid eye disease (TED), according to a study.

In this retrospective cohort study, 20 patients with active moderate-severe to sight-threatening TED were followed over 4 years (Weeks 24, 52 and 78) to evaluate the clinical efficacy of MMF dosing and side effects.

The median duration of treatment with MMF was 76 weeks, with 10% of patients stopping treatment prior to 24 weeks. More than half of patients (55%) had dysthyroid optic neuropathy (DON).

Clinical efficacy was seen in all patients (8/8) without DON at 24 weeks, 87.5% (7/8) at 52 weeks, and 83.3% (5/6) at 78 weeks. Clinical Activity Score (CAS) decreased from baseline from 2.78±1.99 to 0.50±0.58, 0.50±0.82 and, 1.00±1.30 at 78 weeks, respectively.

In patients with DON, improvements were seen in 90% (9/10) at 24 weeks, 100% (7/7) at 52 weeks and 100% (4/4) at 78 weeks. CAS scores were significantly reduced from 2.55±1.54 to 0.83±1.27, 1.00±1.17, and 0.63±0.95, respectively. Improvements in Gorman score, visual acuity, and soft tissue inflammation parameters were also noted.

Quah Qin Xian N, Alnahrawy A, Akshikar R, et al. Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol. 2021;15:1921-1932. doi: 10.2147/OPTH.S305717. PMID: 34007144; PMCID: PMC8121682.


Related Articles
Gail Devers Partners with the Graves’ Community to Focus on Thyroid Eye Disease
Jul 15, 2021
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease
Jul 12, 2021
Teprotumumab improves clinical course of TED
Jun 01, 2021
Click to access the login or register cheese